|
End-of-day quote
Korea S.E.
2026-09-02
|
5-day change | 1st Jan Change | ||
| 5,630.00 KRW | -4.41% |
|
+6.03% | -17.45% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 2020-03-25 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 2025-03-26 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 2024-03-28 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 2023-03-29 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.41% | +6.03% | -23.51% | - | 102M | ||
| +1.37% | -3.43% | +93.26% | +420.10% | 46.24B | ||
| +1.24% | -1.78% | +19.31% | +60.55% | 26.57B | ||
| -0.51% | -7.03% | -21.47% | -41.94% | 6.94B | ||
| +0.24% | -1.51% | +5.49% | +132.42% | 5.94B | ||
| +0.61% | +0.13% | +17.12% | +74.09% | 3.35B | ||
| +2.25% | -0.78% | -33.03% | +1,829.25% | 2.53B | ||
| -0.29% | +3.63% | +98.18% | +14.70% | 2.24B | ||
| +5.30% | +5.41% | +29.15% | +33.27% | 2.03B | ||
| -2.60% | -9.18% | -16.43% | -55.31% | 1.88B | ||
| Average | +0.33% | -0.89% | +16.81% | +274.13% | 9.78B | |
| Weighted average by Cap. | +1.10% | -3.35% | +50.38% | +270.13% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















